Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
J Psychoactive Drugs. 2022 Jul-Aug;54(3):284-293. doi: 10.1080/02791072.2021.1957188. Epub 2021 Aug 2.
Neuroleptic malignant syndrome caused by atypical antipsychotic drugs may present in an atypical manner without symptoms such as hyperthermia and/or muscle rigidity. A detailed description of atypical neuroleptic malignant syndrome induced by atypical antipsychotic drugs, practical information to distinguish neuroleptic malignant syndrome from other related conditions, and the diagnostic criteria that may be used to settle the diagnosis of atypical neuroleptic malignant syndrome are highlighted in this paper. This study was conducted searching PubMed and Science Direct, resulting in 525 articles. 26 case reports that met inclusion criteria were identified. Atypical neuroleptic malignant syndrome was found to develop mainly in male patients suffering from schizophrenia (14 cases) and bipolar disorder (2), and was induced by clozapine (6 cases), olanzapine (5 cases), aripiprazole and quetiapine (4 cases). Muscle rigidity did not develop in patients treated with clozapine and quetiapine, whereas a lack of hyperthermia was common with aripiprazole and clozapine treatment. Atypical neuroleptic malignant syndrome is a difficult matter, especially when symptoms of hyperthermia or muscle rigidity is lacking, but using Levenson's or Adityanjee and Aderibigbe's criteria may increase it detectability, can permit earlier intervention and prevent development of life-threatening typical neuroleptic malignant syndrome.
神经阻滞剂恶性综合征由非典型抗精神病药物引起时,可能表现为不典型,没有高热和/或肌肉僵直等症状。本文重点阐述了非典型神经阻滞剂恶性综合征的非典型表现、与其他相关疾病的鉴别要点、有助于诊断非典型神经阻滞剂恶性综合征的诊断标准。该研究通过检索 PubMed 和 Science Direct 数据库获得 525 篇文章,共纳入 26 例符合标准的病例报告。结果显示,非典型神经阻滞剂恶性综合征主要发生于男性精神分裂症(14 例)和双相障碍(2 例)患者,由氯氮平(6 例)、奥氮平(5 例)、阿立哌唑和喹硫平(各 4 例)引起。氯氮平和喹硫平治疗者无肌肉僵直,而阿立哌唑和氯氮平治疗者常见无高热。非典型神经阻滞剂恶性综合征比较棘手,特别是高热和肌肉僵直不明显时,但采用 Levenson 或 Adityanjee 和 Aderibigbe 标准可提高其检出率,有助于早期干预,预防发生危及生命的典型神经阻滞剂恶性综合征。